Literature DB >> 12736807

Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis.

Hirokazu Kanegane1, Maria Marluce dos Santos Vilela, Yue Wang, Takeshi Futatani, Hiroyoshi Matsukura, Toshio Miyawaki.   

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is characterized clinically by chronic non-malignant lymphoproliferation and autoimmunity and is caused by a genetic defect in programmed cell death (apoptosis). Most patients with ALPS have heterozygous mutations in the Fas gene. We describe an 11-year-old Brazilian boy with hepatosplenomegaly, lymphadenopathy, hemolytic anemia, and hypergammaglobulinemia since early infancy. T cell lines from the patient were defective in Fas-mediated apoptosis. He was diagnosed as having ALPS and found to have a novel Fas gene mutation (IVS4+1G>A). In addition, he presented with glomerulonephritis in infancy. An aunt and uncle who had the same Fas mutations also had histories of glomerulonephritis. Although glomerulonephritis is common in Fas-deficient mice, it is infrequent in human ALPS. Corticosteroid therapy ameliorated the glomerulonephritis in our patient, as well as his lymphoproliferation, anemia, and hypergammaglobulinemia. This study suggests that glomerulonephritis is one of the characteristic features of ALPS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12736807     DOI: 10.1007/s00467-003-1087-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  10 in total

Review 1.  Autoimmune lymphoproliferative syndrome, a disorder of apoptosis.

Authors:  C E Jackson; J M Puck
Journal:  Curr Opin Pediatr       Date:  1999-12       Impact factor: 2.856

2.  Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.

Authors:  C E Jackson; R E Fischer; A P Hsu; S M Anderson; Y Choi; J Wang; J K Dale; T A Fleisher; L A Middelton; M C Sneller; M J Lenardo; S E Straus; J M Puck
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

3.  Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease.

Authors:  J Wu; J Wilson; J He; L Xiang; P H Schur; J D Mountz
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

4.  Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II.

Authors:  J Wang; L Zheng; A Lobito; F K Chan; J Dale; M Sneller; X Yao; J M Puck; S E Straus; M J Lenardo
Journal:  Cell       Date:  1999-07-09       Impact factor: 41.582

5.  Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder.

Authors:  Y Kasahara; T Wada; Y Niida; A Yachie; H Seki; Y Ishida; T Sakai; F Koizumi; S Koizumi; T Miyawaki; N Taniguchi
Journal:  Int Immunol       Date:  1998-02       Impact factor: 4.823

6.  The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations.

Authors:  A K Vaishnaw; E Toubi; S Ohsako; J Drappa; S Buys; J Estrada; A Sitarz; L Zemel; J L Chu; K B Elkon
Journal:  Arthritis Rheum       Date:  1999-09

7.  Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.

Authors:  G H Fisher; F J Rosenberg; S E Straus; J K Dale; L A Middleton; A Y Lin; W Strober; M J Lenardo; J M Puck
Journal:  Cell       Date:  1995-06-16       Impact factor: 41.582

8.  The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis.

Authors:  A J Infante; H A Britton; T DeNapoli; L A Middelton; M J Lenardo; C E Jackson; J Wang; T Fleisher; S E Straus; J M Puck
Journal:  J Pediatr       Date:  1998-11       Impact factor: 4.406

9.  A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease.

Authors:  M C Sneller; S E Straus; E S Jaffe; J S Jaffe; T A Fleisher; M Stetler-Stevenson; W Strober
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

10.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.

Authors:  F Rieux-Laucat; F Le Deist; C Hivroz; I A Roberts; K M Debatin; A Fischer; J P de Villartay
Journal:  Science       Date:  1995-06-02       Impact factor: 47.728

  10 in total
  6 in total

Review 1.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.

Authors:  Thomas Hehlgans; Klaus Pfeffer
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

Review 2.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

3.  Lymphadenopathy, splenomegaly, intermittent neutropenia, and acute kidney injury: Answers.

Authors:  Katie Sullivan; Rose Chami; Rachel Pearl
Journal:  Pediatr Nephrol       Date:  2019-08-29       Impact factor: 3.714

Review 4.  Autoimmunity in Primary Immunodeficiencies (PID).

Authors:  Grace T Padron; Vivian P Hernandez-Trujillo
Journal:  Clin Rev Allergy Immunol       Date:  2022-06-01       Impact factor: 8.667

5.  Differential regulation of miR-146a/FAS and miR-21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS-FAS).

Authors:  Lia Furlaneto Marega; Marcelo Ananias Teocchi; Maria Marluce Dos Santos Vilela
Journal:  Clin Exp Immunol       Date:  2016-05-24       Impact factor: 4.330

6.  Case Report: Atypical Manifestations Associated With FOXP3 Mutations. The "Fil Rouge" of Treg Between IPEX Features and Other Clinical Entities?

Authors:  Micaela Gentile; Maurizio Miano; Paola Terranova; Stefano Giardino; Maura Faraci; Filomena Pierri; Enrico Drago; Daniela Verzola; Gianmarco Ghiggeri; Enrico Verrina; Andrea Angeletti; Barbara Cafferata; Alice Grossi; Isabella Ceccherini; Gianluca Caridi; Francesca Lugani; Lorenzo Nescis; Enrico Fiaccadori; Luca Lanino; Daniela Fenoglio; Edoardo La Porta
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.